| Fabry Disease
Elfabrio vs Galafold
Side-by-side clinical, coverage, and cost comparison for fabry disease.Deep comparison between: Elfabrio vs Galafold with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsGalafold has a higher rate of injection site reactions vs Elfabrio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Galafold but not Elfabrio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Elfabrio
Galafold
At A Glance
IV infusion
Every 2 weeks
Alpha-galactosidase A enzyme replacement
Oral
Every other day
Pharmacological chaperone (alpha-Gal A)
Indications
- Fabry Disease
- Fabry Disease
Dosing
Fabry Disease 1 mg/kg administered by IV infusion every 2 weeks; initial infusion rates are weight-based with separate schedules for ERT-experienced and ERT-naive patients.
Fabry Disease 123 mg orally once every other day; swallow capsule whole on an empty stomach (no food or caffeine for at least 2 hours before and 2 hours after dosing).
Contraindications
—
—
Adverse Reactions
Most common (>=15%) infusion-associated reactions, nasopharyngitis, headache, diarrhea, fatigue, nausea, back pain, pain in extremity, sinusitis
Serious hypersensitivity reactions including anaphylaxis, infusion-associated reactions, membranoproliferative glomerulonephritis
Most common (>=10%) Headache, nasopharyngitis, urinary tract infection, nausea, pyrexia
Postmarketing Angioedema
Pharmacology
Alpha-galactosidase A enzyme replacement; pegunigalsidase alfa-iwxj is internalized and transported into lysosomes where it reduces accumulated globotriaosylceramide (Gb3) caused by alpha-galactosidase A deficiency in Fabry disease.
Migalastat is a pharmacological chaperone that reversibly binds to the active site of alpha-galactosidase A (alpha-Gal A), stabilizing the enzyme and restoring its trafficking from the endoplasmic reticulum to the lysosome, where it degrades glycosphingolipid substrates GL-3 and lyso-Gb3 in patients with amenable GLA variants causing Fabry disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Elfabrio
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Galafold
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Elfabrio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Galafold
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Elfabrio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Galafold
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Fabry Disease - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ElfabrioView full Elfabrio profile
GalafoldView full Galafold profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.